A groundbreaking 2025 study published in Science Advances reveals a specific mechanism by which NAD+ may fight Alzheimer’s disease (AD). Researchers discovered that aging and AD are linked to “dysfunctional alternative splicing events” (ASEs)—essentially errors in how gene instructions are assembled. The study found that augmenting NAD+ levels corrects these splicing errors. Specifically, NAD+ regulates a protein called EVA1C, which is critical for neuronal development but found at reduced levels in the hippocampus of AD patients. In mouse models carrying pathological Tau, NAD+ treatment improved memory retention. However, when the researchers genetically blocked EVA1C, the memory-boosting benefits of NAD+ completely disappeared, proving this protein is essential for the therapy to work.
- Disclaimers
This information is for educational purposes only and should not be interpreted as medical advice.
The study discussed was conducted on human cells , C. elegans (worms) , and mouse models. Further research is needed to confirm these specific mechanisms in humans.
Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications.
Ai R, Mao L, Jin X, et al. NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C. Sci Adv. 2025;11(eady9811).
#NAD #Alzheimers #BrainHealth #Longevity #NewResearch
NAD+, Alzheimer’s reversal, EVA1C protein, RNA splicing explained, Science Advances 2025, Ai et al study, tau pathology, NMN benefits, NR supplements, neuroprotection mechanism, hippocampus memory, anti-aging science, genetic splicing errors, mouse model Alzheimer’s, C elegans aging